Oliver Wyman

oliverwyman.com

Oliver Wyman is a global leader in management consulting. With offices in 50+ cities across nearly 30 countries, Oliver Wyman combines deep industry knowledge with specialized expertise in strategy, operations, risk management, and organization transformation. The firm has more than 5,000 professionals around the world who help clients optimize their business, improve their operations and risk profile, and accelerate their organizational performance to seize the most attractive opportunities. Oliver Wyman is a wholly owned subsidiary of Marsh & McLennan Companies.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Business Insights

EYEPOINT PHARMACEUTICALS ANNOUNCED A DEBT REFINANCING WITH SILICON VALLEY BANK FOR $45 MILLION IN CREDIT FACILITIES

EyePoint Pharmaceuticals, Inc. | March 10, 2022

news image

A pharmaceutical company, EyePoint Pharmaceuticals, Inc.dedicated to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders, announced that it has entered into a loan agreement with Silicon Valley Bank to replace its existing credit facility with CRG Servicing LLC for senior secured credit facilities for $45 million (CRG). A $30 million term loan facility and an asset-based revolving credit facility of up to $15 million will be used to replac...

Read More

Business Insights

RESILIENCE ESTABLISHES MULTI-PRODUCT DEVELOPMENT AND MANUFACTURING COLLABORATION WITH TAKEDA’S PLASMA-DERIVED THERAPIES BUSINESS UNIT

Resilience | February 16, 2022

news image

National Resilience, Inc. a technology-focused manufacturing company dedicated to broadening access to complex medicines, announced a manufacturing services agreement with Takeda’s Plasma-Derived Therapies Business Unit. As part of the agreement, Resilience will focus on supporting the development and manufacture of multiple products in Takeda’s plasma-derived medicines portfolio out of its facility in Mississauga, Ontario. “I...

Read More

HOW AI IS HELPING PHARMA COPE WITH SUPPLY CHAIN DISRUPTION

EPM Magazine | June 25, 2020

news image

As the Covid-19 crisis continues to unsettle global economies and business sectors worldwide, pharma companies are facing huge disruption to their supply chains and clinical research. And while research into potential Covid-19 vaccines and treatments is speeding along, the pandemic has slowed or brought to a halt clinical trials for other diseases, with organisations like Eli Lilly and other big name pharma’s’ putting the brakes on non Covid-19 trial activity. In fact,...

Read More

Pharmacy Market

NEXUS PHARMACEUTICALS RECEIVES FDA APPROVAL FOR STERILE WATER FOR INJECTION, USP

Businesswire | July 26, 2023

news image

Nexus Pharmaceuticals announced it has received U.S. Food and Drug Administration (FDA) approval for Sterile Water for Injection, USP in 10mL and 20mL Single-Dose Vials. According to the FDA and the FD&C Act, the product is considered bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Sterile Water for Injection USP, of Hospira, Inc. Furthermore, the FDA has granted CGT (competitive generic therapy) designation for the 20mL presentation of steri...

Read More
news image

Business Insights

EYEPOINT PHARMACEUTICALS ANNOUNCED A DEBT REFINANCING WITH SILICON VALLEY BANK FOR $45 MILLION IN CREDIT FACILITIES

EyePoint Pharmaceuticals, Inc. | March 10, 2022

A pharmaceutical company, EyePoint Pharmaceuticals, Inc.dedicated to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders, announced that it has entered into a loan agreement with Silicon Valley Bank to replace its existing credit facility with CRG Servicing LLC for senior secured credit facilities for $45 million (CRG). A $30 million term loan facility and an asset-based revolving credit facility of up to $15 million will be used to replac...

Read More
news image

Business Insights

RESILIENCE ESTABLISHES MULTI-PRODUCT DEVELOPMENT AND MANUFACTURING COLLABORATION WITH TAKEDA’S PLASMA-DERIVED THERAPIES BUSINESS UNIT

Resilience | February 16, 2022

National Resilience, Inc. a technology-focused manufacturing company dedicated to broadening access to complex medicines, announced a manufacturing services agreement with Takeda’s Plasma-Derived Therapies Business Unit. As part of the agreement, Resilience will focus on supporting the development and manufacture of multiple products in Takeda’s plasma-derived medicines portfolio out of its facility in Mississauga, Ontario. “I...

Read More
news image

HOW AI IS HELPING PHARMA COPE WITH SUPPLY CHAIN DISRUPTION

EPM Magazine | June 25, 2020

As the Covid-19 crisis continues to unsettle global economies and business sectors worldwide, pharma companies are facing huge disruption to their supply chains and clinical research. And while research into potential Covid-19 vaccines and treatments is speeding along, the pandemic has slowed or brought to a halt clinical trials for other diseases, with organisations like Eli Lilly and other big name pharma’s’ putting the brakes on non Covid-19 trial activity. In fact,...

Read More
news image

Pharmacy Market

NEXUS PHARMACEUTICALS RECEIVES FDA APPROVAL FOR STERILE WATER FOR INJECTION, USP

Businesswire | July 26, 2023

Nexus Pharmaceuticals announced it has received U.S. Food and Drug Administration (FDA) approval for Sterile Water for Injection, USP in 10mL and 20mL Single-Dose Vials. According to the FDA and the FD&C Act, the product is considered bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Sterile Water for Injection USP, of Hospira, Inc. Furthermore, the FDA has granted CGT (competitive generic therapy) designation for the 20mL presentation of steri...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us